CD44 and cancer: In comparison, MMP9 localized on the surface of cancer cells can also activate latent TGF-β, albeit in a CD44-dependent manner [75].CD44 provides a cell surface docking receptor for proteolytically-activeMMP9, resulting in TGF-β-induced myofibroblasts formation [75].